Navigation Links
Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
Date:3/16/2011

SAN DIEGO and OSAKA, Japan, March 16, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have suspended clinical activities in an ongoing Phase 2 study examining the safety and effectiveness of the investigational combination therapy pramlintide/metreleptin for the treatment of obesity. The clinical study was voluntarily halted to investigate a new antibody-related laboratory finding with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.

"The safety of patients in our clinical programs is of paramount concern to the companies. We have taken this precaution so that we can thoroughly investigate this finding," said Orville Kolterman, M.D., senior vice president and chief medical officer of Amylin Pharmaceuticals. "Together with our partner, Takeda, we are committed to working closely with clinical investigators, regulators and outside experts to determine the best path forward."

Independent of the partnership agreement with Takeda, Amylin confirmed that today's announcement does not affect Amylin's lipodystrophy development program investigating the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

About Pramlintide/Metreleptin Combination Treatment

Pramlintide acetate is a synthetic analog of the natural hormone amylin, a neurohormone secreted by the pancreas that is known to play a role in the regulation of appetite, food intake and postprandial glucose concentrations. To date, approximately 8,000 individuals have received pramlintide in clinical trials, including more than 950 in obesity studies. Metreleptin (methionyl recombinant leptin; r-metHuLeptin) is an analog of human leptin, a neur
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amylin Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
2. Amylin Pharmaceuticals to Present at the 2011 ISI Annual Conference
3. Amylin Pharmaceuticals Reports 2010 Financial Results
4. Amylin Pharmaceuticals to Webcast Year-End Financial Results
5. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
7. Amylin Pharmaceuticals Reports Third Quarter Financial Results
8. Amylin Pharmaceuticals to Present at the 2010 Credit Suisse Healthcare Conference
9. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
10. Amylin Pharmaceuticals to Webcast Third Quarter Results
11. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... and HERZLIYA PITUACH, Israel , Dec. ... IMNP ) announced today that its Board of ... succeeding Dr. Daniel Teper who continues as Chief ... of Immune,s Board of Directors since 2013. Immune,s ... delighted to represent the interest of shareholders and to continue ...
Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
...   Sanofi (EURONEXT: SAN and NYSE: ... Scientific American Diabetes Association Sessions,2011, the results of three studies ... and/or,Apidra ® with the insulin delivery device,SoloSTAR ® ... of hypoglycemia vs those,using a premixed insulin product. ...
... June 24, 2011 Advanced BioHealing, Inc. ... technology in the field of regenerative medicine, today announced ... Lewin Group (Falls Church, VA) that showed the addition ... chronic diabetic foot ulcers (DFUs) resulted in a significant ...
Cached Medicine Technology:Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 2Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 3Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 4Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 5Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 6Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 7Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 2Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 3Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 4Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 5
(Date:12/17/2014)... Poor students get more fruits and vegetables at school than ... the opposite is true for students from wealthier families. ... may give a healthy boost to poor students, diets, according ... income level, students all ate a similar amount of fruits ... was published recently in the journal Preventive Medicine . ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... health, but a growing body of evidence shows the ancient ... In fact, the benefits were similar to those of ... Chu, a doctoral candidate at Harvard University,s Health Policy Program ... that people randomly assigned to take yoga classes saw improvements ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Cancer researchers ... possible underlying genetic causes of deadly malignant pleural mesothelioma. ... research on their website. Click here to read ... University of Hawaii Cancer Center, and New York’s Langone ... malignant pleural mesothelioma patients in an effort to ...
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Health ... solutions, announced today that it has received Patient ... Assurance (NCQA) for its Disease Management (DM) Programs ... disease (COPD), coronary heart disease and diabetes. This ... NCQA for Health Dialog’s Disease Management (DM) Programs, ...
Breaking Medicine News(10 mins):Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2
... Real Parental Reassurance, NEW YORK, May 22 ... of biosensor and microprocessor technologies for,use in portable ... for its latest homecare wellness product using SPO,s ... traditional home baby,monitor market., Each year, there ...
... at ... Alma Mater, ... of two fellowships totaling $500,000,in honor of former Chief Executive Officer ... Dr. Garnier, who,received his Masters of Business Administration from the school ...
... SUPPORTS AMERICA,S NEXT GENERATION OF SCIENTISTS, WASHINGTON, ... (the Alliance) announced today the establishment of the,Alliance/Merck ... access to higher education and degrees in science,technology, ... possible,through a $4 million grant from The Merck ...
... Reach of Novel Technology, N. BILLERICA, Mass., ... of cellular bioenergetics, announced today,that Primetech Corporation will ... consumables in Japan., "Japan,s contribution to research ... have seen with the recent acquisition of Millennium ...
... 22 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... leading plasma-based pharmaceutical companies in the,People,s Republic of ... from the Bureau of Health in Guangxi Province ... to a more favorable,location with a wider coverage ...
... projected to climb at double-digit rates, ... according to Millennium Research Group, WALTHAM, Mass., ... for Craniomaxillofacial (CMF) Devices 2008 report,the plate and screw fixation ... nearly $300 million in 2012, driven in part by the ...
Cached Medicine News:Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 2Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 3Health News:GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business 2Health News:GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business 3Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 2Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 3Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 4Health News:Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market 2Health News:China Biologic Products Announces Approval for the Relocation of Fang Cheng Plasma Collection Station and for the Procurement of Excess Clinical Plasma 2Health News:China Biologic Products Announces Approval for the Relocation of Fang Cheng Plasma Collection Station and for the Procurement of Excess Clinical Plasma 3Health News:Craniomaxillofacial Plate & Screw Market To Grow to Almost $300 Million by 2012 2
... is a electronic medical records software for ... The Medical Office Records does more than ... designed to follow the flow of your ... previous encounters to establishing new examination records ...
... ChartMaker is a modular, Electronic Medical Record ... Windows to create a patient chart. ChartMaker ... E & M compliant patient notes, medical reports, ... template driven, ChartMaker is designed to be installed ...
... The eCHARMS suite comprises the ... 2000 product line. Currently, there ... signature & enterprise-wide disclosure reporting. ... new HIM management tool. These ...
Clinician's Desktop provides users the tools needed to coordinate information. Utilizing client/server technology Clinicians Desktop provides users with electronic medical records....
Medicine Products: